Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3236-6
Abstract: The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome. MM remains an incurable disease with unavoidable… read more here.
Keywords: relapsed refractory; based regimen; pom dex; therapy ... See more keywords
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure–response analysis of pomalidomide
Sign Up to like & getrecommendations! Published in 2021 at "Pediatric Research"
DOI: 10.1038/s41390-020-01304-6
Abstract: Background Pomalidomide, an immunomodulatory drug, was investigated for pediatric brain tumors. The objectives of this analysis were to characterize the PK of pomalidomide and to examine exposure–response relationship in pediatric patients with recurrent or progressive… read more here.
Keywords: pomalidomide; pediatric patients; brain tumors; exposure response ... See more keywords
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-51442-2
Abstract: Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b study (ClinicalTrials.gov., NCT03143985) to determine the primary endpoints of safety, tolerability, and… read more here.
Keywords: tgf type; kinase inhibitor; pomalidomide; type receptor ... See more keywords
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a “real‐world” study: Polish Myeloma Group experience
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Haematology"
DOI: 10.1111/ejh.13106
Abstract: Patients with relapsed/refractory multiple myeloma (RRMM) have poor prognosis. Pomalidomide is an immunomodulatory compound that has demonstrated activity in MM patients with disease refractory to lenalidomide and bortezomib. read more here.
Keywords: relapsed refractory; refractory multiple; myeloma; efficacy safety ... See more keywords
Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents.
Sign Up to like & getrecommendations! Published in 2017 at "Current oncology"
DOI: 10.3747/co.24.3572
Abstract: Despite progressive treatments with tandem stem-cell transplantation, patients with incurable myeloma eventually succumb to relapsed or refractory disease if left untreated. Promising agents such as proteasome inhibitors and immunomodulating imide drugs (imids), including the newer-generation… read more here.
Keywords: patient hypersensitive; desensitization patient; desensitization; pomalidomide ... See more keywords